210 related articles for article (PubMed ID: 35121903)
1. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.
Arrieta VA; Chen AX; Kane JR; Kang SJ; Kassab C; Dmello C; Zhao J; Burdett KB; Upadhyayula PS; Lee-Chang C; Shilati J; Jaishankar D; Chen L; Gould A; Zhang D; Yuan J; Zhao W; Ling X; Burks JK; Laffleur B; Amidei C; Bruce JN; Lukas RV; Yamaguchi JT; Cieremans D; Rothschild G; Basu U; McCord M; Brat DJ; Zhang H; Cooper LAD; Zhang B; Sims P; Cloughesy TF; Prins R; Canoll P; Stupp R; Heimberger AB; Horbinski C; Iwamoto FM; Rabadan R; Sonabend AM
Nat Cancer; 2021 Dec; 2(12):1372-1386. PubMed ID: 35121903
[TBL] [Abstract][Full Text] [Related]
2. ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis.
Arrieta VA; Duerinck J; Burdett KB; Habashy KJ; Geens W; Gould A; Schwarze JK; Dmello C; Kim KS; Saganty R; Chen L; Moscona A; McCord M; Lee-Chang C; Horbinski CM; Zhang H; Stupp R; Neyns B; Sonabend AM
Clin Cancer Res; 2024 Jan; 30(2):379-388. PubMed ID: 37939133
[TBL] [Abstract][Full Text] [Related]
3. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H
Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114
[TBL] [Abstract][Full Text] [Related]
4. Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma.
Qazi MA; Vora P; Venugopal C; Adams J; Singh M; Hu A; Gorelik M; Subapanditha MK; Savage N; Yang J; Chokshi C; London M; Gont A; Bobrowski D; Grinshtein N; Brown KR; Murty NK; Nilvebrant J; Kaplan D; Moffat J; Sidhu S; Singh SK
Cancer Res; 2018 Sep; 78(17):5023-5037. PubMed ID: 29945963
[TBL] [Abstract][Full Text] [Related]
5. Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma.
Indraccolo S; Lombardi G; Fassan M; Pasqualini L; Giunco S; Marcato R; Gasparini A; Candiotto C; Nalio S; Fiduccia P; Fanelli GN; Pambuku A; Della Puppa A; D'Avella D; Bonaldi L; Gardiman MP; Bertorelle R; De Rossi A; Zagonel V
Clin Cancer Res; 2019 Mar; 25(6):1828-1837. PubMed ID: 30514778
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.
Giménez N; Martínez-Trillos A; Montraveta A; Lopez-Guerra M; Rosich L; Nadeu F; Valero JG; Aymerich M; Magnano L; Rozman M; Matutes E; Delgado J; Baumann T; Gine E; González M; Alcoceba M; Terol MJ; Navarro B; Colado E; Payer AR; Puente XS; López-Otín C; Lopez-Guillermo A; Campo E; Colomer D; Villamor N
Haematologica; 2019 Mar; 104(3):576-586. PubMed ID: 30262568
[TBL] [Abstract][Full Text] [Related]
7. Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults.
Olivet MM; Brown MC; Reitman ZJ; Ashley DM; Grant GA; Yang Y; Markert JM
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568717
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects.
Wang X; Lu J; Guo G; Yu J
Cell Death Dis; 2021 Mar; 12(4):299. PubMed ID: 33741903
[TBL] [Abstract][Full Text] [Related]
9. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
10. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy.
White K; Connor K; Meylan M; Bougoüin A; Salvucci M; Bielle F; O'Farrell AC; Sweeney K; Weng L; Bergers G; Dicker P; Ashley DM; Lipp ES; Low JT; Zhao J; Wen P; Prins R; Verreault M; Idbaih A; Biswas A; Prehn JHM; Lambrechts D; Arijs I; Lodi F; Dilcan G; Lamfers M; Leenstra S; Fabro F; Ntafoulis I; Kros JM; Cryan J; Brett F; Quissac E; Beausang A; MacNally S; O'Halloran P; Clerkin J; Bacon O; Kremer A; Chi Yen RT; Varn FS; Verhaak RGW; Sautès-Fridman C; Fridman WH; Byrne AT
Ann Oncol; 2023 Mar; 34(3):300-314. PubMed ID: 36494005
[TBL] [Abstract][Full Text] [Related]
11. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis.
Mizumoto Y; Kyo S; Mori N; Sakaguchi J; Ohno S; Maida Y; Hashimoto M; Takakura M; Inoue M
Cancer Sci; 2007 May; 98(5):652-8. PubMed ID: 17388789
[TBL] [Abstract][Full Text] [Related]
12. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
Cardona AF; Rojas L; Wills B; Ruiz-Patiño A; Abril L; Hakim F; Jiménez E; Useche N; Bermúdez S; Mejía JA; Ramón JF; Carranza H; Vargas C; Otero J; Archila P; Rodríguez J; Rodríguez J; Behaine J; González D; Jacobo J; Cifuentes H; Feo O; Penagos P; Pineda D; Ricaurte L; Pino LE; Vargas C; Marquez JC; Mantilla MI; Ortiz LD; Balaña C; Rosell R; Zatarain-Barrón ZL; Arrieta O
Clin Transl Oncol; 2019 Oct; 21(10):1364-1373. PubMed ID: 30798512
[TBL] [Abstract][Full Text] [Related]
14. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
15. Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma.
Omar AI
J Vis Exp; 2014 Oct; (92):e51638. PubMed ID: 25407354
[TBL] [Abstract][Full Text] [Related]
16. Immunologic Features in De Novo and Recurrent Glioblastoma Are Associated with Survival Outcomes.
Alanio C; Binder ZA; Chang RB; Nasrallah MP; Delman D; Li JH; Tang OY; Zhang LY; Zhang JV; Wherry EJ; O'Rourke DM; Beatty GL
Cancer Immunol Res; 2022 Jul; 10(7):800-810. PubMed ID: 35507919
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition.
Cagnol S; Rivard N
Oncogene; 2013 Jan; 32(5):564-76. PubMed ID: 22430215
[TBL] [Abstract][Full Text] [Related]
18. ERK1/2 acts as a switch between necrotic and apoptotic cell death in ether phospholipid edelfosine-treated glioblastoma cells.
Melo-Lima S; Lopes MC; Mollinedo F
Pharmacol Res; 2015; 95-96():2-11. PubMed ID: 25749008
[TBL] [Abstract][Full Text] [Related]
19. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
Watanabe S; Hayashi H; Haratani K; Shimizu S; Tanizaki J; Sakai K; Kawakami H; Yonesaka K; Tsurutani J; Togashi Y; Nishio K; Ito A; Nakagawa K
Cancer Sci; 2019 Jan; 110(1):52-60. PubMed ID: 30390416
[TBL] [Abstract][Full Text] [Related]
20. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
[Next] [New Search]